Abstract:Objective To investigate the value of 24 h dynamic electrocardiogram (ECG) and levels of serum high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP) and monocyte chemoattractant protein (MCP-1) in the diagnosis of silent myocardial ischemia (SMI) in elderly patients with coronary heart disease (CHD). Methods A total of 120 elderly patients with CHD admitted to our hospital from January 2022 to January 2024 were recruited, and according to 24 h dynamic ECG, they were divided into SMI group (n=63) and non-SMI group (NSMI, n=57). The peripheral blood levels of hs-CRP, NT-proBNP and MCP-1 were compared between two groups with independent sample t test. Pearson correlation analysis was conducted to determine the relationship between serum hs-CRP, NT-proBNP and MCP-1 levels and total ischemia burden in the SMI group. Receiver operating characteristic (ROC) curve was drawn to analyze the diagnostic value of the three indicators for SMI in elderly CHD patients. SPSS statistics 23.0 was used for statistical analysis. Results The 24 h dynamic ECG revealed the overall detection rate of SMI was 52.50% (63/120) in the elderly CHD patients. The peripheral blood levels of NT-proBNP, hs-CRP and MCP-1 were significantly higher in the SMI group than the NSMI group (P<0.05). Pearson correlation analysis suggested that the levels of the three indicators were positively correlated with total burden of myocardial ischemia in the SMI group (r=0.568,0.446,0.394; P<0.05). ROC curve analysis indicated that NT-proBNP (OR=0.824,95%CI 0.751-0.896), hs-CRP (OR=0.728,95%CI 0.638-0.818) and MCP-1 (OR=0.630,95%CI 0.529-0.731) had certain value in the diagnosis of SMI in elderly CHD patients, and NT-proBNP alone had the highest diagnostic efficiency. The combination of the three indicators (OR=0.886,95%CI 0.829-0.943) improved the diagnostic efficiency of each indicator alone. Conclusion The combination of peripheral blood hs-CRP, NT-proBNP and MCP-1 has good potential in the diagnosis of SMI in elderly CHD patients, and the three indicators are expected to become biomarkers for the diagnosis of SMI.